Teva Pharmaceutical Industries Limited (TEVA) Shares Active after Upgrade at Bank of America Corporation

Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares fell back in value on Tuesday January 31 on slower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a upgraded rating.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.60% fell 140 points, or 0.7%, to 19,833, with 26 of the 30 blue-chip companies trading lower. Nike, Inc. NKE, -1.10% down 2.4% and Intel Corp. INTC, -1.70% off 1%, were leading losses.

The S&P 500 SPX, -0.33% was off by 10 points, or 0.5%, to 2,270 with seven of the 11 main sectors trading lower. Industrials, consumer-discretionary, and technology shares were the worst performers, while real estate and utilities stocks attracted buyers.

The health-care sector, which was down in early trade, rebounded after President Trump called for scaling back drugmaker’s regulation, lowering taxes and prices of medicines.

The Nasdaq Composite COMP, -0.25% declined 31 points, or 0.6%, to 5,581.

Analysts at Bank of America Corporation upgraded shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) from Neutral to Buy today. With a rating of Buy on the stock, Teva Pharmaceutical Industries Limited has a 52-week high of $62.31. The one-year price target of $44.70 is higher than the opening price of $32.35, causing a fair amount of other analysts to report on the stock recently. Stock prices often shift to the upside on recommendations and new price targets of professional brokerage firms.

Yesterday Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares last traded at $32.89, a decrease of $1.64 over the previous closing price. Opening at $32.35, they fluctuated from $32.19 and $32.98 throughout the day.

Teva Pharmaceutical Industries Limited (NYSE: TEVA) currently has a market cap of 33.38B.

Teva Pharmaceutical Industries Limited (NYSE: TEVA) Average Daily Trading Volume

9,454,358 shares traded hands yesterday, 86 percent below the average, out of a total float 904,923,000. lower than normal. Look for trading volume to pick up in the coming days as investors often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these retain teams of analysts researching thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.

Teva Pharmaceutical Industries Limited (NYSE: TEVA) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By identifying trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.

With that in mind, Teva Pharmaceutical Industries Limited (NYSE: TEVA) now has a 50-day MA of $35.45 and 200-day MA of $44.14. It has traded in a 52-week range between $32.11 – 62.310 and today’s last price is 47.22%% lower than the 52 week high of $62.31.

Earnings growth is a critical factor to consider when buying stocks and investors seek companies that have increased their earnings by at least 25% for 3 consecutive years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *